



DAFTAR PUSTAKA

- Abul Kalam Azad, M. & Atiqul Haq, S., 2025, Urinary Tract Infection in Systemic Lupus Erythematosus: Report from A Developing Country, *Mymensingh medical journal: MMJ*, 34(1), 141-152.
- Aliyi, O., Worku, B., Hassen, M. & Muhammed, O.S., 2024, Treatment outcome and survival status among adult patients treated for lupus nephritis in selected tertiary hospitals of Ethiopia, *Scientific Reports*, 14(1).
- Anders, H.J., Saxena, R., Zhao, M. hui, Parodis, I., Salmon, J.E. & Mohan, C., 2020, Lupus nephritis, *Nature Reviews Disease Primers*, 6(1).
- Argolini, L.M., Frontini, G., Elefante, E., Saccon, F., Binda, V., Tani, C., Scotti, I., Carli, L., Gatto, M., Esposito, C., Gerosa, M., Caporali, R., Doria, A., Messa, P., Mosca, M. & Moroni, G., 2021, Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up, *Journal of Nephrology*, 34(2), 389–398.
- Askanase, A.D., Furie, R., Dall’Era, M., Bomback, A.S., Schwarting, A., Zhao, M.H., Bruce, I.N., Khamashta, M., Rubin, B., Carroll, A., Levy, R.A., Vollenhoven, R. van & Urowitz, M.B., 2025, Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic Agents, *Rheumatology and Therapy*, 1-14.
- Calatroni, M., Andrulli, S., Doti, F., Bello, F., Vivo, G. De, Mastrangelo, A., Papa, N. Del, Schioppo, T., Locatelli, L., Reggiani, F. & Moroni, G., 2025, Long-term prognosis of lupus nephritis: comparison between pediatric, adult, and advanced age onset, *Frontiers in Immunology*, 16.
- Deng, J., Huo, D., Wu, Q., Yang, Z. & Liao, Y., 2012, A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis, *Tohoku Journal of Experimental Medicine*, 227(4), 281–288.
- Dima, A., Jurcut, C., Chasset, F., Felten, R. & Arnaud, L., 2022, Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge, *Therapeutic Advances in Musculoskeletal Disease*, *Therapeutic advances in musculoskeletal disease*, 14.
- Durcan, L., Clarke, W.A., Magder, L.S. & Petri, M., 2015, Hydroxychloroquine blood levels in systemic lupus erythematosus: Clarifying dosing controversies and improving adherence, *Journal of Rheumatology*, 42(11), 2092–2097.
- Ekpenyong, H.J., Olaosebikan, H.B., Aliyu, H.H., Babatunde, E.O. & Adelowo, O.O., 2024, Generalized lymphadenopathy as an initial presentation of systemic lupus erythematosus: case report and review of the literature, *Egyptian Rheumatology and Rehabilitation*, 51(1).
- Elhabashy, E.M., Hussein, W.H. & Mahmoud, G.A., 2025, Delayed onset lupus nephritis in the course of systemic lupus erythematosus: Relation to disease activity and therapeutic response, *Egyptian Rheumatologist*, 47(2), 65–69.
- Farah, R.I., Dannoun, E., Abu Shahin, N. & Alryalat, S.A., 2019, Characteristics and histological types of lupus nephritis in a Jordanian tertiary medical center, *BioMed Research International*, 2019(1).



- Feldman, C.H., Hiraki, L.T., Liu, J., Fischer, M.A., Solomon, D.H., Alarcón, G.S., Winkelmayer, W.C. & Costenbader, K.H., 2013, Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004, *Arthritis & Rheumatism*, 65(3), 753–763.
- Furuto, Y., Kawamura, M., Namikawa, A., Takahashi, H. & Shibuya, Y., 2020, Efficacy of High-Dose Mycophenolate Mofetil in Multitarget Therapy for Lupus Nephritis: Two Consecutive Case Reports, *Cureus*.
- Gasparotto, M., Gatto, M., Binda, V., Doria, A. & Moroni, G., 2020, Lupus nephritis: Clinical presentations and outcomes in the 21st century, *Rheumatology (United Kingdom)*, 59, V39–V51.
- Gatto, M., Frontini, G., Calatroni, M., Reggiani, F., Depascale, R., Cruciani, C., Quaglioni, S., Sacchi, L., Trezzi, B., Bonelli, G.D., L’Imperio, V., Vaglio, A., Furlan, C., Zen, M., Iaccarino, L., Sinico, R.A., Doria, A. & Moroni, G., 2024, Effect of Sustained Clinical Remission on the Risk of Lupus Flares and Impaired Kidney Function in Patients With Lupus Nephritis, *Kidney International Reports*, 9(4), 1047–1056.
- Guéry, J.C., 2019, Why Is Systemic Lupus Erythematosus More Common in Women?, *Joint Bone Spine*, 86(3), 297–299.
- Hoover, P.J. & Costenbader, K.H., 2016, Insights into the epidemiology and management of lupus nephritis from the US rheumatologist’s perspective, *Kidney International*, 90(3), 487–492.
- Ichinose, K., Kitamura, M., Sato, S., Fujikawa, K., Horai, Y., Matsuoka, N., Tsuboi, M., Nonaka, F., Shimizu, T., Sumiyoshi, R., Koga, T., Kawashiri, S.Y., Iwamoto, N., Igawa, T., Tamai, M., Nakamura, H., Origuchi, T., Nishino, T. & Kawakami, A., 2020, Comparison of complete renal response and mortality in early- And late-onset lupus nephritis: A multicenter retrospective study of a Japanese cohort, *Arthritis Research and Therapy*, 22(1).
- Indriyani, N.P.D., Kurniari, P.K. & Kambayana, G., 2020, Keberhasilan Terapi Rituximab pada Seorang Pasien dengan Lupus Nephritis Berat: Laporan Kasus, *Intisari Sains Medis*, 11(3), 1144–1151.
- Iwamoto, T. & Niewold, T.B., 2017, Genetics of human lupus nephritis, *Clinical Immunology*, 185, 32–39.
- Jewett, A. & Tseng, H.-C., 2017, Immunotherapy, *Pharmacology and Therapeutics for Dentistry*, pp. 504–529, Elsevier.
- Kapsia, E., Marinaki, S., Michelakis, I., Liapis, G., Sfikakis, P.P., Boletis, J. & Tektonidou, M.G., 2022, Predictors of Early Response, Flares, and Long-Term Adverse Renal Outcomes in Proliferative Lupus Nephritis: A 100-Month Median Follow-Up of an Inception Cohort, *Journal of Clinical Medicine*, 11(17).
- Kazem Mohamed El-Sayed, B., Allam Mohamed, E., Mohamed Rashed, A.-S., Said Abd El-Aziz Shehata, M., Mohamed Ragab Mandour, E. & Mohamed El Syaed, K., 2021, RENAL HISTOPATHOLOGICAL PROFILE IN PATIENTS WITH SILENT LUPUS NEPHRITIS, *Al-Azhar Med. J.(Medicine)*, 50(2), 1281–1292.



- Lai, N.S., Lu, M.C., Chang, H.H., Lo, H.C., Hsu, C.W., Huang, K.Y., Tung, C.H., Hsu, B.B., Wu, C.H. & Koo, M., 2021, A comparison of the correlation of systemic lupus erythematosus disease activity index 2000 (Sledai-2k) and systemic lupus erythematosus disease activity score (sle-das) with health-related quality of life, *Journal of Clinical Medicine*, 10(10).
- Machado-Alba, J.E., Machado-Duque, M.E., Gaviria-Mendoza, A., Duarte-Rey, C. & González-Rangel, A., 2023, Clinical characterization of a cohort of patients treated for systemic lupus erythematosus in Colombia: A retrospective study, *PLoS ONE*, 18(5 May).
- McKeon, K.P. & Jiang, S.H., 2020, Treatment of systemic lupus erythematosus, *Australian Prescriber*, 43(3), 85–90.
- Mejia-Vilet, J.M. & Ayoub, I., 2021, The Use of Glucocorticoids in Lupus Nephritis: New Pathways for an Old Drug, *Frontiers in Medicine*, 8.
- Mikdashi, J. & Nived, O., 2015, Measuring disease activity in adults with systemic lupus erythematosus: The challenges of administrative burden and responsiveness to patient concerns in clinical research, *Arthritis Research and Therapy*, 17(1).
- Morales, E., Sandino, J. & Galindo, M., 2023, Lupus nephropathy beyond immunosuppression: Searching for nephro and cardioprotection, *Frontiers in Nephrology*, 3.
- Mosca, M., Merrill, J.T. & Bombardieri, S., 2007, Systemic Lupus Erythematosus, *Elsevier*.
- Nariswari, I. A. I., Winarti, N. W., Sriwidayanti, N. P., Dewi, I. G. A. S. M., 2022, Gambaran Klinikopatologik Lupus Nefritis di RSUP Sanglah Denpasar Tahun 2016-2020, *Jurnal Medika Udayana*, 11.
- Obrișcă, B., Sorohan, B., Tuță, L. & Ismail, G., 2021, Advances in lupus nephritis pathogenesis: From bench to bedside, *International Journal of Molecular Sciences*, 22(7).
- Parikh, S., Hebert, L. & Rovin, B., 2011, Protecting the kidneys in lupus nephritis, *International Journal of Clinical Rheumatology*, 6(5), 529–546.
- Parikh, S. V., Almaani, S., Brodsky, S. & Rovin, B.H., 2020, Update on Lupus Nephritis: Core Curriculum 2020, *American Journal of Kidney Diseases*, 76(2), 265–281.
- Parikh, S. V., Nagaraja, H.N., Hebert, L. & Rovin, B.H., 2014, Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis, *Clinical Journal of the American Society of Nephrology*, 9(2), 279–284.
- Parker, B. & Bruce, I.N., 2019, Dubois' Lupus Erythematosus and Related Syndromes, *Elsevier*.
- Peña-Vizcarra, Ó.R., Zavala-Miranda, M.F., Juárez-Cuevas, B., Márquez-Macedo, S.E., Hernández-Andrade, A., Nordmann-Gomes, A., Pérez-Arias, A.A., Morales-Buenrostro, L.E. & Mejia-Vilet, J.M., 2024, Effect of antimalarials on clinical outcomes in lupus nephritis, *Rheumatology (United Kingdom)*, 63(8), 2230–2238.
- Peng, W., Tang, Y., Tan, L. & Qin, W., 2018, Clinicopathological study of male and female patients with lupus nephritis: a retrospective study, *International Urology and Nephrology*, 50(2), 313–320.



- Ponticelli, C., Reggiani, F. & Moroni, G., 2021, Old and new calcineurin inhibitors in lupus nephritis, *Journal of Clinical Medicine*, 10(21).
- Quan, X.Y., Chen, H.T., Liang, S.Q., Yang, C., Yao, C.W., Xu, Y.Z., Liu, H.F. & An, N., 2022, Revisited Cyclophosphamide in the Treatment of Lupus Nephritis, *BioMed Research International*, 2022(1).
- Roveta, A., Parodi, E.L., Brezzi, B., Tunesi, F., Zanetti, V., Merlotti, G., Francese, A., Maconi, A.G. & Quaglia, M., 2024, Lupus Nephritis from Pathogenesis to New Therapies: An Update, *International Journal of Molecular Sciences*, 25(16).
- Sachdeva, R. & Pal, R., 2022, The influence of reproductive hormones on systemic lupus erythematosus, *Exploration of Immunology*, 2(3), 351–362.
- Sharma, H., Kaul, A., Mohakuda, S.S., Behera, M.R., Bhadauria, D.S., Agrawal, V., Agarwal, V., Prasad, N., Singh, A. & Patel, M.R., 2023, Clinicopathologic characteristics and outcomes of late onset lupus nephritis: a single centre experience, *Rheumatology International*, 43(10), 1849–1858.
- Shaukat, F., Russinova, L., Seizhanova, B. & Rakhmetova, A., 2019, Lupus nephritis in males; updates to current knowledge, *Journal of Nephro pharmacology*, 8(1).
- Sprangers, B., Monahan, M. & Appel, G.B., 2012, Diagnosis and treatment of lupus nephritis flares - An update, *Nature Reviews Nephrology*, 8(12), 709–717.
- Thong, K.M. & Chan, T.M., 2019, Infectious complications in lupus nephritis treatment: a systematic review and meta-analysis, *Lupus*, 28(3), 334–346.
- Touma, Z., Gladman, D.D. & Urowitz, M.B., no date, Clinical Measures, Metrics, and Indices.
- Tselios, K., Gladman, D.D., Su, J. & Urowitz, M.B., 2016, Does Renin-Angiotensin System Blockade Protect Lupus Nephritis Patients From Atherosclerotic Cardiovascular Events? A Case–Control Study, *Arthritis Care and Research*, 68(10), 1497–1504.
- Tunnicliffe, D.J., Palmer, S.C., Henderson, L., Masson, P., Craig, J.C., Tong, A., Singh-Grewal, D., Flanc, R.S., Roberts, M.A., Webster, A.C. & Strippoli, G.F.M., 2018, Immunosuppressive treatment for proliferative lupus nephritis, *Cochrane Database of Systematic Reviews*, 2018(6).
- You, Y., Zhou, Z., Wang, F., Li, J., Liu, H., Cheng, X., Su, Y., Chen, X., Zheng, H., Sun, Y., Shi, H., Hu, Q., Xu, J., Teng, J., Yang, C. & Ye, J., 2024, Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus: A Randomized Clinical Trial, *JAMA network open*, 7(9), e2432131.
- Yu, C., Li, P., Dang, X., Zhang, X., Mao, Y. & Chen, X., 2022, Lupus nephritis: new progress in diagnosis and treatment, *Journal of Autoimmunity*, 132.
- Zayat, A.S., Mahmoud, K., Md Yusof, M.Y., Mukherjee, S., D’Agostino, M.A., Hensor, E.M.A., Wakefield, R.J., Conaghan, P.G., Edwards, C.J., Emery, P. & Vital, E.M., 2019, Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus, *Rheumatology (United Kingdom)*, 58(2), 304–312.